Hsp90-a potential prognostic marker in CML

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11310%2F13%3A10193353" target="_blank" >RIV/00216208:11310/13:10193353 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023736:_____/13:00010466

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S1079979612001982" target="_blank" >http://www.sciencedirect.com/science/article/pii/S1079979612001982</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.bcmd.2012.11.002" target="_blank" >10.1016/j.bcmd.2012.11.002</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Hsp90-a potential prognostic marker in CML

Popis výsledku v původním jazyce

Heat shock proteins (Hsp) are important for the stability and function of cell proteins and thus for cell survival under physiological as well as stress conditions. Hsps were also reported to play an important role in tumorogenesis including leukemias. In this study we followed up Hsp70 and 90 protein levels in samples from patients with chronic myeloid leukemia (CML) to evaluate these Hsps with regard to their ability to characterize the disease status and disease prognosis. We analyzed 68 samples of total leukocytes of CML patients with different response to therapy with tyrosine kinase inhibitors. The results of Western blot analyses showed that the level of Hsp70 did not change in the course of the disease and did not correlate with response to therapy. In contrast, Hsp90 levels showed good correlation with the disease state. Patients with good response to therapy (major molecular response-MMR, molecular remission-CMR) had low expression levels of Hsp90, similar to those in healthy

Název v anglickém jazyce

Hsp90-a potential prognostic marker in CML

Popis výsledku anglicky

Heat shock proteins (Hsp) are important for the stability and function of cell proteins and thus for cell survival under physiological as well as stress conditions. Hsps were also reported to play an important role in tumorogenesis including leukemias. In this study we followed up Hsp70 and 90 protein levels in samples from patients with chronic myeloid leukemia (CML) to evaluate these Hsps with regard to their ability to characterize the disease status and disease prognosis. We analyzed 68 samples of total leukocytes of CML patients with different response to therapy with tyrosine kinase inhibitors. The results of Western blot analyses showed that the level of Hsp70 did not change in the course of the disease and did not correlate with response to therapy. In contrast, Hsp90 levels showed good correlation with the disease state. Patients with good response to therapy (major molecular response-MMR, molecular remission-CMR) had low expression levels of Hsp90, similar to those in healthy

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NT12392" target="_blank" >NT12392: Studium heterogenity chronické myeloidní leukemie na úrovni profilů aktivních proteinů - využití v prognóze onemocnění</a><br>

Návaznosti

S - Specificky vyzkum na vysokych skolach<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood Cells, Molecules, and Diseases

ISSN

1079-9796

e-ISSN

—

Svazek periodika

50

Číslo periodika v rámci svazku

3

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

6

Strana od-do

184-189

Kód UT WoS článku

000315074500009

EID výsledku v databázi Scopus

—